Compare Davita Inc (DVA) vs iShares MSCI Germany (DAX) (EWG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs iShares MSCI Germany (DAX) — how do they compare? Davita Inc trades at $230.51 (market cap $14.92B), while iShares MSCI Germany (DAX) trades at $41.39. The key difference: Davita Inc is trading nearer its 52-week high, iShares MSCI Germany (DAX) nearer its low. Which is the better fit depends on your goals.
| DVA | EWG | |
|---|---|---|
Market Cap | $14.92B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $235.71 | $44.56 |
52-Week Low | $103.87 | $38.08 |
Enterprise Value | $27.47B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
EWG is trading at $41.23, down 0.63% on the day amid bearish technical signals. The stock faces selling pressure with moving averages indicating a downtrend, though oscillators remain neutral. Recent German economic developments, including healthcare reforms and ECB rate hikes, create a mixed backdrop for European-focused investments.
The outlook remains cautious with technical indicators favoring sellers, while fundamental data is unavailable. Key risks include European economic volatility and regulatory changes. Investors should monitor German economic indicators and company-specific financial disclosures for clearer direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →
